Enhertu Among Drugs In Annual China NRDL Update

Local Companies Dominate But No CAR-Ts

 
• By Xu Hu

The majority of new drugs added to the latest revision of China's NRDL were developed by Chinese companies, although half of the global top 20 pharmas also have new entries. Bispecifics were included for the first time but no CAR-Ts made the cut.

China's National Healthcare Security Administration updated the national reimbursement drug list in late November
China's National Healthcare Security Administration updated the national reimbursement drug list towards the end of November. (Shutterstock)
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from China

More from Market Access